Stock market news

Elektropribor

Electropribor's RAS net profit for 3 months of 2025 amounted to ₽997.94 million, up 52.7% from ₽653.73 million in the previous year. Revenue rose 13.9% to ₽4.68 billion against ₽4.11 billion a year earlier.

EN+ Group

En+ Group's RAS net profit for 3 months of 2025 amounted to ₽6.81 billion against a loss of ₽1.16 billion in the previous year. Revenue amounted to ₽7.87 billion. A year ago, the company had no revenue.

Rosseti Center and Volga Region

Board of Directors of Rosseti Center and Volga Region recommended that dividends be paid for 2024 in the amount of ₽0.050215 per ordinary share. The last day of the purchase of securities to receive dividends is June 30, 2025. Dividend yield may amount to 12.83%.

Stavropolenergosbyt

Board of Directors of Stavropolenergosbyt recommended to pay dividends of ₽0.4703035 per preferred share for 2024. Last day to buy securities for dividends is July 3, 2025. Dividend yield could be as high as 9.35%.

Slavneft-Yaroslavnefteorgsintez

Slavneft-Yanos' RAS net profit for 3 months of 2025 amounted to ₽2.36 billion, up 17.4% from ₽2.01 billion in the previous year. Revenue rose 11% to ₽13.27 billion against ₽11.95 billion a year earlier.

TMK

Pipe Metallurgical Company's RAS net profit for 3 months of 2025 amounted to ₽0.349 billion against a loss of ₽5.8 billion in the previous year. Revenue fell 7.6% to ₽103.6 billion vs. ₽112.1 billion a year earlier.

EL5-Energo

EL5-Energo's RAS net profit for 3 months of 2025 amounted to ₽2 billion, down 9.1% from ₽2.2 billion in the previous year. Revenue increased by 12.1% to ₽19.5 billion vs. ₽17.4 billion a year earlier.

VTB Bank

VTB announced the launch of a new project aimed at attracting patients from CIS countries and other friendly states for treatment in Russia. VTB Medicine service will organize the entire cycle of medical services, providing full support: from finding doctors and clinics to solving transfer and accommodation issues. Potential audience of the project is at lea...

Ozon Pharmaceuticals

Ozon Pharmaceuticals Group at the end of April introduced a new over-the-counter drug Safiston® Neo on the Russian pharmaceutical market. Combined analgesic based on acetylsalicylic acid, caffeine and paracetamol is intended for the treatment of mild to moderate pain syndrome, as well as fever reduction in flu and other acute respiratory diseases. To date, t...

Ozon Pharmaceuticals

Ozone Pharmaceuticals' RAS net profit for 3 months of 2025 amounted to ₽0.429 billion, down 2.8 times from ₽1.2 billion in the previous year. Revenue fell 41.5% to ₽0.708 billion against ₽1.21 billion a year earlier.